Core Viewpoint - The establishment of a joint venture in Hong Kong focused on anti-aging products and solutions, with a registered capital of HKD 50 million, is a strategic move for the company and its partners [1][2]. Group 1: Joint Venture Details - The joint venture agreement was signed on October 27, 2025, among the company and its partners, with ownership stakes of 75%, 20%, and 5% respectively [1]. - The joint venture aims to invest in and operate research and sales of anti-aging products and solutions in Hong Kong and selected Asia-Pacific countries [1]. Group 2: Partner Profiles - Partner I, NAGAWA Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company focused on the development, manufacturing, and commercialization of high-quality drugs, particularly in anti-aging technologies [1]. - Partner II, Mirxes Pte Ltd., is a Singapore-based biotech company specializing in molecular diagnostics, particularly in oncology, and has extensive collaborations with academic institutions for large-scale research [2]. - Mirxes operates two research laboratories, one clinical diagnostic laboratory, one testing laboratory, and two production facilities [2].